News and Announcements
Omni Market Tide Limited Welcome New Chief Financial Officer And Company Secretary
- Published February 06, 2017 6:02PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Omni Market Tide Limited (OMT) advises that Mr Paul Fredericks has replaced Mr Paul Cochrane as the Chief Financial Officer and Company Secretary as of February 6, 2017. OMT would like to personally thank Mr Cochrane for his contributions to the Company and also welcome on board Mr Frederiks.
Mr Frederiks brings more than 30+ years’ experience as a finance and corporate governance executive in the Australian listed sector and extensive knowledge based in listed public company reporting and compliance.
With this, he previously held the position of Chief Financial Officer and Company Secretary positions with Discovery Metals Limited, Geodynamics Limited and Ross Mining NL, and was also appointed Company Secretary of Billabong International Limited, Auzex Resources Limited and China Steel Australia Limited.
Mr Fredericks is a Fellow of CPA Australia, the Australian Institute of Company Directors and the Governance Institute of Australia.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
